• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

古塞库单抗治疗中重度银屑病的超级应答者:误区、现状与未来展望

Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives.

作者信息

Ruiz-Villaverde Ricardo, Vasquez-Chinchay Fiorella, Rodriguez-Fernandez-Freire Lourdes, C Armario-Hita Jose, Pérez-Gil Amalia, Galán-Gutiérrez Manuel

机构信息

Dermatology Department, Hospital Universitario San Cecilio, Avda Conocimiento 33, 18016 Granada, Spain.

Dermatology Department, Hospital Quirón Salud Sagrado Corazón, 41013 Sevilla, Spain.

出版信息

Life (Basel). 2022 Sep 10;12(9):1412. doi: 10.3390/life12091412.

DOI:10.3390/life12091412
PMID:36143449
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9505180/
Abstract

A fast skin clearance is the main goal to achieve in psoriasis treatment. Patients that present a fast and exceptional improvement with treatment are called super-responders (SR). There is no consensus on the definition of SR with respect to psoriasis. Included herein is a retrospective analysis of a multicenter, observational study of real clinical practices including patients with moderate-to-severe plaque PSO undergoing treatment with Guselkumab (GUS). This cross-sectional analysis includes information on patients between February 2019 to February 2022. A SR is a patient that achieved a PASI = 0 at weeks 12 and 24. Analyses have been performed "as observed" using GraphPad Prism version 8.3.0 for Windows (GraphPad Software, San Diego, CA, USA, At baseline, the PASI is significantly correlated with VAS_pruritus, BSA, and DLQI, while DLQI is significantly correlated with VAS_pruritus. Significant correlations increase in number and magnitude over the follow-up time. In relation to the univariate logistic models carried out, only three variables showed a significant association with the super-responder variable: depression, VAS_pruritus, and DLQI.SR patients, who show a faster evolution in PASI and BSA improvement than non-SRs. Based on the results obtained, it would be possible to also include DLQI and VAS_pruritus in the broader concept of the SR.

摘要

快速清除皮肤病变是银屑病治疗的主要目标。在治疗中表现出快速且显著改善的患者被称为超级应答者(SR)。关于银屑病的超级应答者定义尚无共识。本文纳入了一项多中心观察性研究的回顾性分析,该研究涉及实际临床实践中接受古塞库单抗(GUS)治疗的中度至重度斑块状银屑病患者。这项横断面分析涵盖了2019年2月至2022年2月期间患者的信息。超级应答者是指在第12周和第24周达到银屑病面积和严重程度指数(PASI)=0的患者。使用适用于Windows的GraphPad Prism 8.3.0版本(GraphPad Software,美国加利福尼亚州圣地亚哥)进行了“观察性”分析。在基线时,PASI与瘙痒视觉模拟评分(VAS_瘙痒)、体表面积(BSA)和皮肤病生活质量指数(DLQI)显著相关,而DLQI与VAS_瘙痒显著相关。在随访期间,显著相关性的数量和程度均有所增加。关于所进行的单变量逻辑模型,只有三个变量与超级应答者变量显示出显著关联:抑郁、VAS_瘙痒和DLQI。超级应答者患者在PASI和BSA改善方面的进展比非超级应答者更快。根据所得结果,也有可能将DLQI和VAS_瘙痒纳入超级应答者这一更广泛概念中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f83d/9505180/92d64cc93b21/life-12-01412-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f83d/9505180/92d64cc93b21/life-12-01412-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f83d/9505180/92d64cc93b21/life-12-01412-g001.jpg

相似文献

1
Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives.古塞库单抗治疗中重度银屑病的超级应答者:误区、现状与未来展望
Life (Basel). 2022 Sep 10;12(9):1412. doi: 10.3390/life12091412.
2
Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series.中重度银屑病 Guselkumab 治疗的超级应答者:真实临床实践的初步系列研究。
Int J Dermatol. 2022 Aug;61(8):1029-1033. doi: 10.1111/ijd.15784. Epub 2021 Nov 3.
3
Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis.古塞单抗作为中重度银屑病患者接受抗 TNF-α、抗 IL-17 或抗 IL-12/23 治疗后的一种转换策略。
Dermatol Ther. 2022 Oct;35(10):e15760. doi: 10.1111/dth.15760. Epub 2022 Aug 15.
4
Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice.古塞单抗:真实临床实践中的中期疗效、药物存续率和安全性。
Dermatol Ther. 2021 Mar;34(2):e14798. doi: 10.1111/dth.14798. Epub 2021 Feb 7.
5
Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis.古塞库单抗对中度至重度斑块状银屑病患者焦虑、抑郁及生活质量的直接和间接影响:一项中介分析
Dermatol Ther (Heidelb). 2024 Sep;14(9):2577-2589. doi: 10.1007/s13555-024-01250-9. Epub 2024 Aug 23.
6
Guselkumab dosing interval optimization in adult patients with moderate-to-severe psoriasis switching from ustekinumab.乌司奴单抗转换为古塞库单抗治疗中重度斑块状银屑病患者的剂量间隔优化
Dermatol Ther. 2022 Nov;35(11):e15835. doi: 10.1111/dth.15835. Epub 2022 Sep 23.
7
Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).现实生活中使用生物制剂治疗的中度至重度斑块状银屑病患者的患者报告结局与医生报告结局之间的关联(PSO-BIO-REAL)
Dermatol Ther (Heidelb). 2020 Oct;10(5):1099-1109. doi: 10.1007/s13555-020-00428-1. Epub 2020 Aug 6.
8
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.中度至重度斑块状银屑病患者中,ixekizumab与guselkumab的头对头比较:一项随机双盲试验的12周疗效、安全性及反应速度
Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15.
9
A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.一项关于古塞库单抗治疗先前生物治疗难治性银屑病的队列研究:疗效、安全性和依从性。
Int J Clin Pharm. 2022 Jun;44(3):725-730. doi: 10.1007/s11096-022-01400-z. Epub 2022 Apr 5.
10
Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.靶向白细胞介素-17 受体的单克隆抗体治疗银屑病:疗效评价。
Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5. doi: 10.1111/bjd.12025.

引用本文的文献

1
Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis).中度至重度银屑病患者接受比美莫司单抗治疗的超级应答者概况:一项短期真实世界观察——IL PSO(意大利银屑病情况)
Clin Drug Investig. 2025 Jun;45(6):309-315. doi: 10.1007/s40261-025-01440-z. Epub 2025 May 15.
2
Time to Loss of Disease Control following Guselkumab Withdrawal in Relation to Initial Speed of Response: A post hoc Analysis of the VOYAGE 2 Trial.与初始反应速度相关的古塞库单抗撤药后疾病控制丧失时间:VOYAGE 2试验的事后分析
Dermatology. 2024 Dec 9;241(2):133-142. doi: 10.1159/000542344.
3

本文引用的文献

1
Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders).特应性皮炎:背景、目标与未来展望(超级应答者)
Life (Basel). 2022 Aug 4;12(8):1192. doi: 10.3390/life12081192.
2
Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis.古塞单抗作为中重度银屑病患者接受抗 TNF-α、抗 IL-17 或抗 IL-12/23 治疗后的一种转换策略。
Dermatol Ther. 2022 Oct;35(10):e15760. doi: 10.1111/dth.15760. Epub 2022 Aug 15.
3
Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?
Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis.
银屑病患者皮肤病生活质量指数与银屑病面积和严重程度指数的相关性:一项关于银屑病的全球性横断面医疗保健研究。
Acta Derm Venereol. 2024 Mar 12;104:adv20329. doi: 10.2340/actadv.v104.20329.
4
Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).生物制剂在临床实践中的比较有效性和持久性:国际银屑病健康结局观察研究(PSoHO)的第12个月结果
Dermatol Ther (Heidelb). 2024 Jun;14(6):1479-1493. doi: 10.1007/s13555-023-01086-9. Epub 2023 Dec 19.
5
Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation.新策略在中重度银屑病超应答患者中的应用:真实世界疗效 Guselkumab 超应答患者作为疗效和优化的代表
Clin Drug Investig. 2023 Jul;43(7):517-527. doi: 10.1007/s40261-023-01280-9. Epub 2023 Jul 4.
奥马珠单抗与环孢素 A 治疗慢性自发性荨麻疹:我们能否定义更好应答的表型?
An Bras Dermatol. 2022 Sep-Oct;97(5):592-600. doi: 10.1016/j.abd.2022.03.003. Epub 2022 Jul 16.
4
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.药物生存与 Guselkumab、Ixekizumab、Secukinumab、Ustekinumab 和 Adalimumab 在银屑病患者中的治疗有效性和安全性相关。
JAMA Dermatol. 2022 Oct 1;158(10):1131-1141. doi: 10.1001/jamadermatol.2022.2909.
5
Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study.全国性研究:生物治疗难治性银屑病和超应答者的流行情况及特征。
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1284-1291. doi: 10.1111/jdv.18126. Epub 2022 Apr 12.
6
Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases.度普利尤单抗在三种 2 型炎症性疾病中表现出快速起效。
J Allergy Clin Immunol Pract. 2022 Jun;10(6):1515-1526. doi: 10.1016/j.jaip.2022.02.026. Epub 2022 Mar 6.
7
Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series.中重度银屑病 Guselkumab 治疗的超级应答者:真实临床实践的初步系列研究。
Int J Dermatol. 2022 Aug;61(8):1029-1033. doi: 10.1111/ijd.15784. Epub 2021 Nov 3.
8
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.度普利尤单抗为中度至重度特应性皮炎成人患者提供快速且持续的具有临床意义的缓解。
Acta Derm Venereol. 2021 Nov 10;101(11):adv00585. doi: 10.2340/actadv.v101.307.
9
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).古塞单抗治疗 IL-23 可能改变银屑病发病机制:中重度斑块型银屑病患者的 3b 期、随机、双盲、多中心研究的原理和研究方案(GUIDE)。
BMJ Open. 2021 Sep 13;11(9):e049822. doi: 10.1136/bmjopen-2021-049822.
10
Potential predictive biomarkers of adalimumab response in patients with hidradenitis suppurativa.阿达木单抗治疗化脓性汗腺炎患者应答的潜在预测性生物标志物。
Br J Dermatol. 2021 Oct;185(4):804-814. doi: 10.1111/bjd.20097. Epub 2021 May 31.